WNT5A and breast cancer: These observations collectively suggest that in BC aberrant Wnt pathway activation may be a consequence of rise in the expression of positive (e.g. Wnt1, Wnt10b, LRP6, FZD7) or decrease in the expression of negative/antagonists (e.g. Wnt5a, Wnt5bsFRP1, sFRP5, WIF1) components of Wnt pathway [32, 15].